Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 15Endocrine 15Thoracic 6Gastrointestinal 4Dermatologic 4Sarcoma 3Other hematologic neoplasm 2Gynecologic 2Genitourinary 2CNS 2Breast 2Plasma cell 1NET 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 879Leukemia, Lymphocytic, Chronic, B-Cell 560Leukemia 426Precursor Cell Lymphoblastic Leukemia-Lymphoma 331Hematologic Neoplasms 331Myelodysplastic Syndromes 302Leukemia, Myelogenous, Chronic, BCR-ABL Positive 244Lymphoma, Non-Hodgkin 224Recurrence 222Lymphoma 196Neoplasms 195Multiple Myeloma 129Lymphoma, Mantle-Cell 119Lymphoma, Large B-Cell, Diffuse 114Lymphoma, Follicular 114Leukemia, Myelomonocytic, Chronic 89Lymphoma, B-Cell 88Lymphoma, B-Cell, Marginal Zone 85Leukemia, B-Cell 79Burkitt Lymphoma 64Leukemia, Myeloid, Chronic-Phase 57Waldenstrom Macroglobulinemia 56Leukemia, Myeloid 53Hodgkin Disease 47Hematologic Diseases 47Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 45Myeloproliferative Disorders 40Primary Myelofibrosis 39Bronchiolitis Obliterans Syndrome 35Anemia, Refractory, with Excess of Blasts 32

Interventions

trametinib 1dabrafenib 1PLX8394 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Thyroid Carcinoma, Anaplastic × Other hematologic neoplasm × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Fore Biotherapeutics

Phase 1 Terminated
5 enrolled
DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡